Literature DB >> 22160883

In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.

Yara Peluso Cid1, Vinícius Pedrazzi, Valéria Pereira de Sousa, Maria Bernadete Riemma Pierre.   

Abstract

Celecoxib (Cx) shows high efficacy in the treatment of osteoarthritis and rheumatoid arthritis as a result of its high specificity for COX-2, without gastrolesivity or interference with platelet function at therapeutic concentrations. Besides of anti-inflammatory effects, Cx also has a potential role for oral cancer chemoprevention. For these conditions, oral administration in long-term treatment is a concern due to its systemic side effects. However, local application at the site of injury (e.g., buccal inflammation conditions or chemoprevention of oral cancer) is a promising way to reduce its toxicity. In this study, the in vitro characterization of mucoadhesive chitosan (CHT) gels associated to Azone® was assessed to explore the potential buccal mucosal administration of Cx in this tissue. Rheological properties of gels were analyzed by a rheometer with cone-plate geometry. In vitro Cx release and permeability studies used artificial membranes and pig cheek mucosa, respectively. Mucoadhesion were measured with a universal test machine. CHT gels (3.0%) containing 2.0% or 3.0% Az showed more appropriate characteristics compared to the others: pH values, rheology, higher amount of Cx retained in the mucosa, and minimal permeation through mucosa, besides the highest mucoadhesion values, ideal for buccal application. Moreover, the flux (J) and amounts of drug released decreased with increased CHT and Az concentrations. CHT gels (3.0%) associated with 2.0% or 3.0% Az may be considered potential delivery systems for buccal administration of Cx.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160883      PMCID: PMC3299462          DOI: 10.1208/s12249-011-9725-8

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  46 in total

Review 1.  Factors and strategies for improving buccal absorption of peptides.

Authors:  F Veuillez; Y N Kalia; Y Jacques; J Deshusses; P Buri
Journal:  Eur J Pharm Biopharm       Date:  2001-03       Impact factor: 5.571

2.  Characterization of chitosan hydrochloride-mucin interaction by means of viscosimetric and turbidimetric measurements.

Authors:  S Rossi; F Ferrari; M C Bonferoni; C Caramella
Journal:  Eur J Pharm Sci       Date:  2000       Impact factor: 4.384

Review 3.  Oral drug absorption enhancement by chitosan and its derivatives.

Authors:  M Thanou; J C Verhoef; H E Junginger
Journal:  Adv Drug Deliv Rev       Date:  2001-11-05       Impact factor: 15.470

4.  In vitro and in vivo evaluations of the efficacy and safety of skin permeation enhancers using flurbiprofen as a model drug.

Authors:  Jia-You Fang; Tsong-Long Hwang; Chia-Lang Fang; Hsien-Chih Chiu
Journal:  Int J Pharm       Date:  2003-04-14       Impact factor: 5.875

5.  Oral mucosal permeability and stability of transforming growth factor beta-3 in vitro.

Authors:  C A Squier; M J Kremer; A Bruskin; A Rose; J D Haley
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

6.  Enhancing effect of chitosan on peptide drug delivery across buccal mucosa.

Authors:  S Senel; M J Kremer; S Kaş; P W Wertz; A A Hincal; C A Squier
Journal:  Biomaterials       Date:  2000-10       Impact factor: 12.479

7.  Topical inhibition of oral carcinoma cell with polymer delivered celecoxib.

Authors:  Zhi Wang; Raju Polavaram; Stanley M Shapshay
Journal:  Cancer Lett       Date:  2003-07-30       Impact factor: 8.679

8.  Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels.

Authors:  Lee Martin; Clive G Wilson; Fariba Koosha; Ijeoma F Uchegbu
Journal:  Eur J Pharm Biopharm       Date:  2003-01       Impact factor: 5.571

9.  Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell.

Authors:  Zhi Wang; Cesar F Fuentes; Stanley M Shapshay
Journal:  Laryngoscope       Date:  2002-05       Impact factor: 3.325

10.  A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells.

Authors:  G Nishimura; S Yanoma; H Mizuno; K Kawakami; M Tsukuda
Journal:  Jpn J Cancer Res       Date:  1999-10
View more
  5 in total

1.  In vitro evaluation of mucoadhesive films for gingival administration of lidocaine.

Authors:  Cristina Padula; Laura Pozzetti; Valeria Traversone; Sara Nicoli; Patrizia Santi
Journal:  AAPS PharmSciTech       Date:  2013-12       Impact factor: 3.246

2.  Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies.

Authors:  Eder André Estracanholli; Fabíola Silva Garcia Praça; Ana Beatriz Cintra; Maria Bernadete Riemma Pierre; Marilisa Guimarães Lara
Journal:  AAPS PharmSciTech       Date:  2014-07-01       Impact factor: 3.246

3.  Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel.

Authors:  Mahendra Singh; Jovita Kanoujia; Poonam Parashar; Malti Arya; Chandra B Tripathi; V R Sinha; Shailendra K Saraf; Shubhini A Saraf
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

4.  Widefield optical imaging of changes in uptake of glucose and tissue extracellular pH in head and neck cancer.

Authors:  Zhen Luo; Melissa N Loja; D Greg Farwell; Quang C Luu; Paul J Donald; Deborah Amott; Anh Q Truong; Regina Gandour-Edwards; Nitin Nitin
Journal:  Cancer Prev Res (Phila)       Date:  2014-08-19

5.  Evaluation of Mucoadhesive Gels with Propolis (EPP-AF) in Preclinical Treatment of Candidiasis Vulvovaginal Infection.

Authors:  Andresa Aparecida Berretta; Patrícia Alves de Castro; Amanda Henriques Cavalheiro; Vanessa Silveira Fortes; Vinícius Pedro Bom; Andresa Piacezzi Nascimento; Franciane Marquele-Oliveira; Vinícius Pedrazzi; Leandra Naira Zambelli Ramalho; Gustavo Henrique Goldman
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-07       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.